A Phase II trial of an umbilical cord stem cell-based therapy as a treatment for adults with active systemic lupus erythematosus (SLE) who had not responded adequately to standard treatment has failed to meet its primary endpoint, but experts still hold promise about its potential.

The Lupus Foundation of America (LFA)–funded Phase II Mesenchymal Stromal Cells in Systemic Lupus Erythematosus (MiSLE) trial (NCT02633163) was evaluating a single infusion of umbilical cord-derived mesenchymal stromal cells (MSCs). The trial enrolled 81 patients across nine US centres, randomised to a low dose, high dose, or placebo.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The primary endpoint was response at week 24 on a modified SLE Responder Index-4 (SRI-4), which combines measures of disease activity with limits on steroid and other immunosuppressant use, which was achieved by 38.9% of MSC-treated patients compared with 23.1% receiving placebo. While this favoured the MSC group, it did not reach statistical significance.

In the separate cohorts, response rate was 48.1% in the high-dose group, 29.6% in the lower-dose group and 23.1% in the pooled placebo group. Again, the comparison between high dose and placebo was numerical, and was much closer to being statistically significant, achieving a p-value just shy of significance.

Secondary analyses using the unmodified SRI-4 showed significant benefits between the higher dose and its within-cohort placebo group at weeks 12, 16 and 20, with p-values around 0.03-0.04 at each time point.

Using analysis by per-protocol response, which excludes patients with major protocol deviations prior to week 24, including those who received high-dose steroids for non-lupus treatments, the week 24 response was 68.4% with the higher dose versus 30.0% in the placebo group, again being statistically significant.

Scores on the SLE Disease Activity Index (SLEDAI), a measure of lupus disease activity, fell in all three groups. After 12 weeks, median scores declined by four points in both treatment cohorts versus two points with placebo, with the median score of the high dose group decreasing more than the others at 24 weeks.

Serious adverse events (SAEs) occurred in 27.8% of patients receiving MSCs (44.4% of the low-dose cohort and 11.1% of the higher-dose cohort) and 14.8% receiving placebo after 52 weeks, with none of the SAEs being attributed to the study drug.

One death occurred in the placebo group early in the study, but was unrelated, and no deaths occurred among the 54 MSC recipients.

Dr Diane Kamen, professor at Medical University of South Carolina (MUSC) in the division of rheumatology and immunology, and co-author of the study, said: “The improvements in lupus activity we observed, especially among patients who received the higher dose, are promising and give us a clearer direction for future research.”

Investigators said they will evaluate these findings in a confirmatory trial of the higher dose, including evaluation of repeat dosing to determine whether the early responses can be sustained over time.

CAR-T’s promise in lupus

Other cell therapy approaches are being investigated in SLE, specifically CAR T-celltreatments. Bristol Myers Squibb (BMS) is running a Phase II trial (NCT07015983) of zolacabtagene autoleucel (zola-cel), an investigational CD19-targeted CAR T-cell therapy, in SLE. In the UK, there are studies including the Phase I CARLYSLE study (NCT06333483) and the Phase II LUMINA trial (NCT07053800) evaluating safety and long-term remission.

The justification for CAR T-cell treatment, which has been a steadfast mechanism of action (MOA) for blood cancers, is that it can deeply deplete autoreactive B cells and reset the immune system, offering potential drug-free remission for patients with severe, treatment-refractory disease.

Despite the initial excitement about these therapies, some pharmaceutical companies have started to re-evaluate the development of CAR T-cell therapies in lupus.

One such company is Galapagos, which rebranded as Lakefront Biotherapeutics in May 2026 and announced in February 2024 that it would be terminating its lupus CAR-T programme in refractory SLE and confirmed several layoffs for ‘strategic reasons’. It has since exited the CAR-T cell therapy space altogether.

Cell & Gene therapy coverage on Clinical Trials Arena is supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.